Morgan Stanley has maintained an Overweight recommendation on Biogen (NASDAQ:BIIB) as of Wednesday this week, with a one-year price target averaging at $340.33. This indicates a potential upside of 28.84% from the recent closing price of $264.14.
The firm's annual revenue is forecasted to decrease by 4.08% to reach $9,565MM, while the non-GAAP EPS is projected at 15.98. Despite this anticipated dip in revenue, total shares have risen by 0.45% to reach 138,519K in the last quarter, suggesting a bullish outlook with a put/call ratio of 0.77.
Institutional ownership saw a slight decrease, but major shareholders remain committed to the company. These include Primecap Management, Vanguard PRIMECAP Fund Investor Shares, Wellington Management Group, Vanguard Health Care Fund Investor Shares, and Vanguard Total Stock Market Index Fund Investor Shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.